portal vein thrombosis

Clots in the veins of the liver (portal vein thrombosis)

Three subjects were excluded from final analysis because of protocol violation (two patients aged over 65, one patient with portal vein thrombosis).

Portal vein thrombosis may occur.

Prehepatic causes include portal vein thrombosis or congenital atresia.

Portal vein thrombosis, hepatic vein, or other intra-abdominal thrombotic events.

Another post mortem study of three patients showed portal vein thrombosis with fresh thrombus extending from recently injected varices.

The diagnosis of portal vein thrombosis is usually made by ultrasound, computed tomography with contrast or magnetic resonance imaging.

Less common causes include diseases such as hemochromatosis, primary biliary cirrhosis (PBC), and portal vein thrombosis.

Another report also demonstrated the absence of any significent portal venous flow in two patients in whom portal vein thrombosis was subsequently confirmed at necropsy.

In addition to the immunosuppressive toxicities, other risks are associated with the islet transplant procedure itself, including intra-abdominal hemorrhage following the transplant, and portal vein thrombosis.

Any interference with arterial blood supply (including infusion chemotherapy) may be associated with significant morbidity and is contraindicated in the presence of portal hypertension, portal vein thrombosis, or clinical jaundice.

Portal vein thrombosis is a form of venous thrombosis affecting the hepatic portal vein, which can lead to portal hypertension and reduction in the blood supply to the liver.

The serum-ascites albumin gradient (SAAG) is the most useful index for evaluating peritoneal fluid and can help distinguish ascites caused by portal hypertension (cirrhosis, portal vein thrombosis, Budd-Chiari syndrome, etc) from other causes of ascites.

Venous thrombosis may also occur in more unusual places: in the veins of the brain, liver (portal vein thrombosis and hepatic vein thrombosis), mesenteric vein, kidney (renal vein thrombosis) and the veins of the arms.

In other rare conditions generally linked with hypercoagulability, such as cerebral venous thrombosis and portal vein thrombosis, there is insufficient data to state for certain whether thrombophilia screening is helpful, and decisions on thrombophilia screening in these conditions are therefore not regarded as evidence-based.